Solid Biosciences Inc.

Solid Biosciences Inc. is a life sciences company dedicated to developing gene therapy candidates for genetic neuromuscular and cardiac diseases. The company's portfolio includes SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for Catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy. These candidates are at various stages of development with different investment levels. Solid Biosciences focuses on rare neuromuscular and cardiac diseases, integrating internal capabilities such as a vector core, validated animal models, optimized expression cassettes, novel capsids, and regulatory expertise. The company also collaborates with leaders in clinical and research fields. Its business model prioritizes identifying and developing therapies for underserved patients with potentially fatal neuromuscular and cardiac diseases, building innovative libraries of delivery capsids and other enabling technologies, and collaborating with leading experts in the field. The company's mission is to treat and change the course of neuromuscular and cardiac diseases at all stages.